Cardiovascular Drugs Market in KSA & UAE- What’s in store for Pharmacos?

Supratim Majumdar, Industry Manager

Healthcare

20th April, 2011

2

Today’s Presenters

Supratim Majumdar, Industry Analyst

Frost & Sullivan

Tanu Chopra, Assistant Manager, Corporate Communications,Frost & Sullivan

3

Research Aim and Key Deliverables

Research Aim

• The aim of this research service is to present an analysis of the Cardiovascular Drugs Market

in KSA and UAE.

Key Deliverables

• Quantifying the size and growth forecasts of the cardiovascular drugs market in KSA and

UAE from 2010 to 2017 by product segments

• Providing insight into the industry challenges, market drivers, and market restraints during the

forecast period

• Identifying key participants of the market and quantifying company market shares by product

segments

• Providing further insight into the competitive environment

• Identifying opportunities for current and new market participants based on a strength,

weakness, opportunities, and threats (SWOT) analysis

4

Market Scope and Segmentation

Market Scope:

Countries covered for the study are:

� Kingdom of Saudi Arabia (KSA)

� United Arab Emirates (UAE)

Market Segmentation:

Antihypertensive

Antidyslipidemic

OthersMark

et

Segm

ents Antihypertensive

Antidyslipidemic

Others

Antihypertensive

Antidyslipidemic

5

Market Overview

� Cardiovascular disease (CVD) is the main cause of disability and premature death through the world in general and in KSA and UAE in particular.

� KSA and UAE population is achieving high percentages of cardiovascular diseases prevalence, due to sedentary lifestyle, mimicking western food habits, smoking, etc.

� The total KSA cardiovascular drugs market generated revenue of $172.8 million in 2010.Revenues are expected to increase to $537.1 with a CAGR of 17.6 percent.

� The total UAE cardiovascular drugs market generated revenue of $100.2 million in 2010.Revenues are expected to increase to $292.4 million with a CAGR of 16.5 percent.

� Within the market, antihypertensives held the largest share of almost 60.0 percent of the revenues in 2010, followed by antidyslipidemics, which help a 37.0 percent share and the others segment with around a share of 3.0 percent.

6

Market Overview Contd.

� At present, there are around 16 players competing in the KSA market. Around 80.0 of the total market is controlled by top 4 players.

� In UAE, around 11 participants are competing in the cardiovascular drugs market. Top 4 players command around 60.0 percent of the market.

� Within antihypertensives, ACE Inhibitors and ARBs are most preferred and used drug classes in both of the markets.

� Statins is the undisputed most used drug class among antidyslipidemics in both the markets.

� Foreign pharmaceutical companies command the majority market share due to innovative products, generic coverage by local companies, fewer number of local companies with limited manufacturing capacity.

7

Market Drivers and Restraints

Long TermLong TermMid TermMid TermShort TermShort Term

Dri

vers

Restr

ain

ts

Rising incidence of life style diseases

Mandatory health insurance

Rising ageing population

Rising health awareness

Newer & easier launches of combination drugs

Rising incidence of life style diseases

Mandatory health insurance

Rising incidence of life style diseases

Mandatory health insurance

Patent expiry and launches of lesser value generics

Government promoting usage of generics

Stringent regulatory system

Low patient compliance

8

Current Market Size and Growth Trends: KSA

Cardiovascular Drugs Market: Revenue Forecast (KSA), 2010 - 2017

0

100

200

300

400

500

600

Years

Mark

et R

evenue (M

illion U

SD

)

Market Revenue(Million USD) 173 537

2010 2017

9

Cardiovascular Drugs Market – Segment Analysis: KSA

Cardiovascular Drugs Market: Market Segments (KSA), 2010

Others 3%

Antihypertensive 60%

Lipid Lowering 37%

10

Market Share Analysis: KSA

Total Cardiovascular Drugs Market: Market Share Analysis (KSA), 2010

Top 4 Players

80%

Others

20%

Top 4 Players

80%

Others

20%

11

Cardiovascular Drugs Market: Revenue Forecast (UAE), 2010 - 2017

0

100

200

300

Years

Mark

et R

evenue (M

illion U

SD

)

Market Revenue(Million USD) 100 292

2010 2017

Current Market Size and Growth Trends: UAE

12

Others,

2.41%

Lipid

Lowering,

36.54%

Anti

Hypertensive

61.2 %

Cardiovascular Drugs Market Segment (UAE), 2010

Cardiovascular Drugs Market – Segment Analysis: UAE

13

Market Share Analysis: UAE

Total Cardiovascular Drugs Market: Market Share of Key Players (UAE), 2010

Top 4 Players

80%

Others

20%

14

Next Steps

� Request a proposal for or Growth Partnership Services or Growth Consulting Services to support you and your team to accelerate the growth of your company. (myfrost@frost.com) 1-877-GoFrost (1-877-463-7678)

� Join us at our annual Growth, Innovation, and Leadership 2011: A Frost &

Sullivan Global Congress on Corporate Growth (www.gil-global.com)

� Register for the next Chairman’s Series on Growth: Driving Innovation – The What, Why, and How. Visions and Benchmarks as the Innovation Key

(October 5th) (http://www.frost.com/growth)

� Register for Frost & Sullivan’s Growth Opportunity Newsletter and keepabreast of innovative growth opportunities(www.frost.com/news)

15

Your Feedback is Important to Us

Growth Forecasts?

Competitive Structure?

Emerging Trends?

Strategic Recommendations?

Other?

Please inform us by rating this presentation.

What would you like to see from Frost & Sullivan?

Frost & Sullivan’s Growth Consulting can assist with your growth strategies

16

http://twitter.com/frost_sullivan

Follow Frost & Sullivan on Facebook, LinkedIn, SlideShare, and Twitter

http://www.facebook.com/FrostandSullivan

http://www.linkedin.com/companies/4506

http://www.slideshare.net/FrostandSullivan

17

For Additional Information

Supratim Majumdar

Industry Analyst

Healthcare

(033) 6160-6666

supratim.majumdar@frost.com

Anish Charles

Asst Manger Corporate Communications – South Asia

(91) 22 66072019

anishc@frost.com

Dr. Ajay Prasad Sharma

Industry Manager

Healthcare

(022) 6160-6666

AjaykumarS@frost.com

Tanu Chopra

Asst. Manager - Corporate Communications - MENA

(91) 22 66072037

tanu.chopra@frost.com